1.	A Study for Patients With Small-Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12253, I1Y-MC-JFBD, NCT01025284
2.	A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12848, I1Y-MC-JFBF, NCT01059643
3.	A Study of LY2523355 in Patients With Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12847, I1Y-MC-JFBE, NCT01416389
4.	A Study for Patients With Advanced Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11618, I1Y-MC-JFBA, NCT01214629
5.	A Dose-Escalation Study for Patients With Advanced Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11619, I1Y-MC-JFBB, NCT01214642
6.	A Study of LY2523355 in Patients With Solid Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2523355-001, NCT01358019